Last reviewed · How we verify
QLF31907
At a glance
| Generic name | QLF31907 |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors (PHASE1, PHASE2)
- A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors (PHASE1)
- Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QLF31907 CI brief — competitive landscape report
- QLF31907 updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI